Anti-cxcr1 compositions and methods
AssigneeThe Regents of the University of Michigan
InventorsMax S. Wicha, Christophe Ginestier
Life of this patent
Estimating the term…
Abstract
The present invention provides methods of treating cancer by administering an IL8-CXCR1 pathway inhibitor (e.g., an anti-CXCR1 antibody or Repertaxin) alone or in combination with an additional chemotherapeutic agent such that non-tumorigenic and tumorigenic cancer cells in a subject are killed. The present invention also provides compositions and methods for detecting the presence of and isolating solid tumor stem cells in a patient (e.g., based on the presence of CXCR1 or FBXO21).
Claims16
A method of detecting solid tumor stem cells comprising:
- detecting CXCR1+ or FBXO21+ solid tumor stem cells from a tissue sample taken from a tumor of a subject.
An isolated population of cancer stem cells that are:
- a) tumorigenic;
- and
- b) CXCR1+ or FBXO21+.
A method for treating a subject having a tumor, comprising:
- administering a compound to said subject, wherein said compound is a CXCR1 or FBXO21 antagonist or an IL8-CXCR1 signaling pathway antagonist.
Dependencies are inferred from the claim text.